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ABSTRACT 
Objectives:  To determine the percentage of neonates with sepsis, on treatment with standard recommended dose of intravenous 
ciprofloxacin, who had the serum ciprofloxacin Peak concentration: Minimum inhibitory concentration (Cmax:MIC), within the 
acceptable range. 
Design:  Observational study design 
Intervention: In the Neonatology ICU, ciprofloxacin was initiated at a dose of 10mg/kg, twice daily in 95 neonates diagnosed with 
sepsis.  On day 3 of ciprofloxacin, blood specimens were collected to measure the trough and peak concentrations of ciprofloxacin 
and were measured by high performance liquid chromatography. The MIC was measured if the blood culture was positive. When the 
blood culture was negative, the reference values for the MIC from ‘The Clinical and Laboratory Standard Institute Guidelines’ were 
adopted. 
Main outcomes: Minimum inhibitory concentration and serum concentrations of ciprofloxacin 
Results:  Blood culture was positive in 14 babies. The mean (±SD) trough concentrations of ciprofloxacin in term, preterm and very 
preterm neonates was 3.21(±1.99), 2.54 (±1.26) and 4.01(±1.80) μg/mL respectively. The mean (±SD) peak concentration of serum 
ciprofloxacin in term, preterm and very preterm neonates was, 12.55 (±4.945) 8.68(±3.61) and 12.07(±3.63) μg/mL, respectively.  
The percentage of neonates who achieved the acceptable Cmax /MIC ratio was predicted to be 74.07% if the strain was sensitive, 
7.41% if intermediate and zero for resistant strains. 
Conclusion: The current recommended dose of intravenous ciprofloxacin in neonates in India may be adequate for treating sepsis 
due to susceptible organisms. For the treatment of sepsis caused by organisms with intermediate susceptibility, higher dosing 
regimens may be needed. 
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INTRODUCTION 
Neonatal sepsis which refers to a group of physical and 
laboratory findings in response to invasive infection 
within the first thirty days of life,
1
 is ranked high among 
the common causes of death in neonates . The incidence 
of neonatal sepsis in India is 30 per 1000 live-births
.2
 
According to the 2010 WHO statistics, neonatal sepsis 
accounts for 6% and 7% mortality among children less 
than five years of age, worldwide and in India 
respectively. 
3
 
According to National Neonatal Perinatal Database 
(2002-03), the most common cause of sepsis is 
Klebsiella pneumoniae, followed by Staphylococcus 
aureus and Escherchia coli in babies born both within 
and outside the hospital. Majority of Klebsiella 
pneumoniae isolates are sensitive to amikacin (114/365, 
31.23%), followed by ciprofloxacin (102/381, 26.8%) 
among inborn babies. Most of the Staphylococcus 
aureus isolates, were sensitive to vancomycin (11/28, 
32.3%) and ciprofloxacin (27/85, 31.8%) in the babies 
born outside. Most of the E.coli isolates were sensitive 
to Amikacin, followed by ciprofloxacin.
2
 
Ciprofloxacin, with concentration dependent killing, is 
safe
4,5
 and efficacious in sepsis produced by multi-
resistant organisms.
6–8
 Zelenitsky et al and Kashuba et al 
have reported a C
max
/MIC ratio of >10 to be adequate to 
prevent resistance to this drug. 
 9–11
   
 With a lower Cmax 
in children compared to adults, it was suggested that 
ciprofloxacin needs to be administered at a dose of 10 
mg/kg, eight hourly for resistant organisms. 
12 
Ciprofloxacin was eliminated slower in neonates (t1/2 
2.73 h) compared to the 1 ± 5 year age group (t1/2 1.28 
h) 
13
. Differences in body weight, hepatic and renal 
function between preterm and term babies, suggested 
the need for different dosing regimens for antibiotics 
like gentamicin.
14 
 
The goal of this study was to determine the incidence of 
preterm and term neonates who attained therapeutically 
acceptable Cmax/MIC ratio, at the current 
recommended dose of 10 mg/kg, twice daily, when 
treated for sepsis. 
MATERIALS AND METHODS 
The study was approved by the Institutional Review 
Board of our hospital. Babies admitted to the 
Neonatology intensive care unit and who required IV 
ciprofloxacin were recruited into the study, after 
obtaining written informed consent from the parent. 
Only babies above 28 weeks of gestational age and 
treated with IV ciprofloxacin for minimum of three days 
were included. And babies who were, critically ill, or in 
shock were excluded. Baseline details such as age, sex, 
birth weight, measured biochemical parameters and 
concurrent medications were recorded.  
 After specimen was collected for blood culture, 
ciprofloxacin was initiated in babies having suspected 
bacterial sepsis. The dose of ciprofloxacin was 10 mg 
/kg /dose, administered as a 30 minute IV infusion. 
Sample collection for ciprofloxacin assay was done on 
Day 3 (dose 5 or dose 6). Both specimens for measuring 
trough and peak ciprofloxacin concentration were 
collected into polypropylene eppendorfs. Peak 
specimens were collected within 10 minutes after 
discontinuing ciprofloxacin infusion. It was ensured that 
specimens were not collected from the same limb that 
ciprofloxacin was administered. Specimens were 
centrifuged, serum separated and stored at -70° C till 
analysis.  
The blood culture and sensitivity report was followed up 
for 7 days and MIC was estimated in cases which were 
culture positive. Clinical and Laboratory Standard 
Institute’s 2011 supplement on “Performance standards 
for antimicrobial susceptibility, report that an organism 
is considered to be sensitive, have intermediate 
sensitivity and resistant to ciprofloxacin if the MIC for 
ciprofloxacin is <1, 2 and >4, respectively. This criteria 
for interpreting sensitivity to ciprofloxacin does not hold 
for gonococci. For babies with sterile blood culture, the 
above three MIC values were used to calculate 
Cmax/MIC.  
High Performance Liquid Chromatography (HPLC) 
Assay  
The samples were analyzed for ciprofloxacin 
concentration by high performance liquid 
chromatography, using Discovery ®HS C18 column 
(25cm x 4.6mm, 5µm).  The mobile phase was 14.5mM 
phosphate buffer with pH3 (75%) and methanol (25%), 
at a flow rate of 1ml/minute and detected at 277nm. 
Samples were extracted by simple protein precipitation 
using zinc sulphate and methanol, with ornidazole as 
internal standard. Imprecision calculated as the interday 
coefficients for the quality control (5µg/ml) was 4.2%. 
There were no interferences from the medications 
commonly administered within this population. 
RESULTS 
 A total of 95 neonates were recruited into the study 
from June 2010 to June 2011. Of which 30 babies were 
very preterm (28-31 wks), 35 moderately preterm (32-
36 wks) and 30 term (37 weeks and above). The mean 
(SD) ciprofloxacin peak and trough concentrations are 
reported in table 1.  
As seen in table 2, there was poor correlation between 
both the age and birth weight with ciprofloxacin 
concentrations in all the three gestational age groups. 
One way Anova with bonferroni correction showed no 
significant difference in the trough (p value =0.121) or 
peak measurements (p value =0.765) between the 
groups.  
Blood culture isolates were positive in 18 babies (19%) 
and MIC was done for 14 blood culture isolates. The 
organisms isolated were B. Cepacia (n=6), Klebsiella 
(n=4), Staphylococcus Aureus (n=2), Enterococcus 
(n=1), E.coli (n=1) and non fermenting gram negative 
bacilli (n=1). Five of the strains were sensitive to 
ciprofloxacin (Staphylococcus Aureus, B. Cepacia, 
Klebsiella and GFNB), three (Enterococci, B.Cepacia) 
had intermediate sensitivity and 6 strains 
(Staphylococcus Aureus, B.Cepacia, Klebsiella.E.coli) 
were resistant to ciprofloxacin.  
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Table 1: The mean (sd) ciprofloxacin levels and the co efficient of variation of the peak and trough values of the three 
gestational age groups. 
Parameters 
Very preterm 
(n=30) 
Moderately preterm 
(n=30) 
Term 
(n=30) 
Mean (sd) Trough (µg/ml) 4.01 (±1.80) 2.54  (±1.26) 3.21  (±1.99) 
Mean (sd) Peak (µg/ml) 12.07  (±3.63) 8.68  (±3.61) 12.55 (±4.945) 
Co efficient of variation of trough 
values (%) 
48.8 49.2 70.3 
Co efficient of Variation of Peak 
values (%) 
36.4 41.8 44.6 
n- Number of subjects, sd- standard deviation, µg/ml- microgram/millilitre 
 
Table 2: Correlation  between the age and ciprofloxacin levels and birth weight and ciprofloxacin levels in all the  three  
gestational age groups 
Correlation 
Very preterm 
(n=30) 
Moderately preterm 
(n=30) 
Term 
(n=30) 
Age and trough -0.36 0.23 -0.01 
Age and Peak 0.39 -0.22 -0.1 
Birth weight and trough -0.04 0.22 -0.18 
Birth weight and peak -0.136 0.22 -0.05 
n- Number of subjects 
 
The MIC of ciprofloxacin for sensitive strains, strains 
with intermediate sensitivity and resistant strains ranged 
from 0.023 to 0.75 μg/mL, 2 ug/ml and from 4 to 32 
μg/mL respectively. 
The Cmax/MIC for sensitive strains was above 10. The 
Cmax/MIC for strains of intermediate sensitivity to 
ciprofloxacin ranged from 4.09 to 9.62. And that for 
resistant strains ranged from 0.31 to 3.47.  
Among the babies with sterile blood culture reports, 
74.07% of them would have Cmax/MIC >10 if all grew 
organisms sensitive to ciprofloxacin. Only 7.41% would 
have Cmax/MIC>10 if they grew organisms with 
intermediate sensitivity and none would attain the 
required Cmax/MIC if they grew resistant strains.  
DISCUSSION 
Ciprofloxacin serum concentration was not significantly 
different between babies in the three  gestational age 
groups. The probable reason being that changes with 
respect to body water, liver and kidney maturation may 
not affect ciprofloxacin pharmacokinetics in neonates. A 
detailed pharmacokinetic study is required to explain 
this, which at the same time may be extremely difficult 
due to ethical considerations regarding number of blood 
samples in critically ill neonates.  
The trough and peak concentrations (collected within 10 
minutes of the end of infusion) of ciprofloxacin 
measured in term and preterm neonates in this study 
were higher compared to that in neonates from North 
India, in whom the mean trough and peak measurements 
(collected 15  minutes after  the end of infusion) ranged 
from 0.7 to 1.0 μg/ml and from 2.3 to 3.0 μg/ml 
respectively.
15
 Van den Oever, H.L. et al  and Bannon, 
M.J et al also reported ciprofloxacin trough and peak 
measurements, in the lower range.
13, 16
 The increased 
concentration in peak and trough could be attributed to 
genetic variability contributing to difference in 
metabolism and clearance. 
Blood culture growth was followed up till 7days, as 
most of the culture reports were positive by about 72 
hours.
17, 18
 B.Cepacia was the most common organism 
isolated but the MIC for each strain was different. Since 
the time point of the incidence of sepsis with this 
organism was different, the implication was that the 
source of infection was different. 
In neonates with culture positive reports, the Cmax/MIC 
was above 10 for sensitive strains but for strains of 
intermediate sensitivity or resistant to ciprofloxacin the 
target Cmax/MIC was not reached. Surprisingly in babies 
with sterile culture reports, inspite of the higher 
concentration of ciprofloxacin in our population, 
Cmax/MIC would be inadequate (ie <10)  in more than 
25% of patients, if infected with sensitive organisms.  
And if infected with organisms of intermediate 
sensitivity only 7.41% of babies would achieve adequate 
Cmax/MIC. If the organism showed resistance to 
ciprofloxacin, no baby would achieve an adequate 
Cmax/MIC. The wide inter-patient variability in trough 
and peak concentration of ciprofloxacin especially in 
term babies may be a reason for promoting emergence 
of resistance even if dosing was based on weight. This is 
supported by the lack of correlation between birth 
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weight and serum ciprofloxacin concentration in 
neonates. Our neonates may need to be treated with a 
higher dose to improve Cmax/MIC and to check 
promotion of further resistance to ciprofloxacin. But to 
our knowledge more work needs to be done using higher 
doses and studying their side effects in neonates.  
CONCLUSION 
The current recommended dose of intravenous 
ciprofloxacin might be adequate for treating sepsis due 
to susceptible organisms, in the Indian neonate 
population. However higher dosing regimens may need 
to be adopted, after confirming its safety in neonates, 
when ciprofloxacin is used for organisms with 
intermediate susceptibility or with resistant organisms. 
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